Richmond Brothers Inc. Has $983,000 Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Richmond Brothers Inc. boosted its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 25.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 642,339 shares of the biotechnology company’s stock after acquiring an additional 131,557 shares during the period. Heron Therapeutics accounts for 0.6% of Richmond Brothers Inc.’s portfolio, making the stock its 22nd largest position. Richmond Brothers Inc.’s holdings in Heron Therapeutics were worth $983,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Y Intercept Hong Kong Ltd acquired a new stake in Heron Therapeutics during the 3rd quarter worth $39,000. Argent Advisors Inc. acquired a new stake in Heron Therapeutics during the 4th quarter worth $31,000. Capstone Investment Advisors LLC acquired a new stake in Heron Therapeutics during the 3rd quarter worth $45,000. Glenmede Trust Co. NA grew its holdings in Heron Therapeutics by 49.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 10,578 shares during the period. Finally, Cutter & CO Brokerage Inc. grew its holdings in Heron Therapeutics by 69.6% during the 4th quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 13,600 shares during the period. Institutional investors and hedge funds own 80.01% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $4.00 target price on shares of Heron Therapeutics in a report on Friday, February 28th. StockNews.com lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 8th.

Heron Therapeutics Stock Up 3.8 %

HRTX opened at $2.48 on Wednesday. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The company has a fifty day simple moving average of $1.87 and a 200 day simple moving average of $1.75. The stock has a market cap of $377.78 million, a P/E ratio of -13.78 and a beta of 1.55.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The firm had revenue of $40.78 million during the quarter, compared to the consensus estimate of $37.37 million. On average, equities research analysts expect that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.